*Gilead Sciences INC (GILD) Stake Held by Finemark National Bank & Trust

April 16, 2018 - By Cynthia Ashman

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate LogoBig Money Sentiment decreased to 0.8 in Q4 2017. It has change of 0.23, from 2017Q3’s 1.03. The ratio dived due to GILD positioning: 95 sold and 545 reduced. 104 funds took stakes and 411 increased stakes. Investors holded 957.62 million in 2017Q3 but now own 972.68 million shares or 1.57% more. Wealthtrust Axiom Limited holds 0.51% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD) for 19,317 shs. Cutter Brokerage has 0.6% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 20,505 shs. Richard Bernstein Advisors Limited Liability Co stated it has 50 shs or 0% of all its holdings. Tiger Mgmt stated it has 0.43% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). American Century Cos holds 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD) or 3.39M shs. Vantage Inv Limited Liability Com, a Pennsylvania-based fund reported 3,541 shs. Parallax Volatility Advisers Limited Partnership owns 0.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 95,337 shs. Bessemer Gp Incorporated holds 0.01% or 40,033 shs. Ftb Advsrs reported 0.51% in Gilead Sciences, Inc. (NASDAQ:GILD). Citadel Ltd Limited Liability Company accumulated 0.1% or 2.21M shs. Baystate Wealth Mngmt Ltd Liability Corp, Massachusetts-based fund reported 936 shs. Coldstream Mngmt reported 6,927 shs. Clear Harbor Asset Mngmt Llc reported 11,195 shs stake. Twin Mngmt holds 0.34% or 97,720 shs in its capital. Benedict Fincl Advsr has 24,341 shs.

GILD registered $39.51 million net activity with 0 insider purchases and 17 selling transactions since January 2, 2018. $3.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by MARTIN JOHN C on Tuesday, January 2. On Tuesday, January 16 $8.02 million worth of stock was sold by Meyers James R. $1.18 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H. 5,000 Gilead Sciences, Inc. (NASDAQ:GILD) shs with value of $401,566 were sold by Washington Robin L. WILSON GAYLE E also sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, February 9.

The holdings In Gilead Sciences Inc (GILD) was rose owned by Finemark National Bank & Trust. According to 2017Q4 Securities and Exchange filling the decrease is 341.82%. 45,277 shares were bought by Finemark National Bank & Trust as the company’s stock rose 1.93% while stock markets declined. The institutional investor is holding 58,523 shares, compared to the 13,246 from the previous quarter. And the announced value of the health care company is $4.19M for the 2017Q4. For a total of 136,878 shares it reduced its holding in General Electric Co (NYSE:GE) by 304,446 shares in the quarter, and has cut its stake in .

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Total analysts of 15 have positions in Gilead Sciences (NASDAQ:GILD) as follows: 8 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 53%. Since October 19, 2017 according to StockzIntelligence Inc Gilead Sciences has 27 analyst reports. The stock rating was downgraded by Argus Research to “Hold” on Monday, November 13. The stock rating was maintained by Barclays Capital with “Overweight” on Tuesday, March 6. On Thursday, November 30 the stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Maxim Group. The stock rating was maintained by Maxim Group with “Buy” on Tuesday, February 6. On Wednesday, February 7 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Wednesday, November 8 Mizuho maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Buy” rating. On Monday, February 5 the firm has “Buy” rating given by Mizuho. On Friday, January 26 the firm has “Buy” rating given by Jefferies. The company rating was maintained by Credit Suisse on Wednesday, January 3. On Wednesday, February 7 Leerink Swann maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating. Leerink Swann has “Market Perform” rating and $83 target.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.